Johnson & Johnson (JNJ)


NYSE - NYSE Real Time Price. Currency in USD
118.13+0.86 (+0.73%)
At close: 4:00 PM EDT
People also watch:
PGMRKKOPFEXOM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open117.78
Prev Close117.27
Bid117.85 x 400
Ask118.29 x 500
Day's Range117.39 - 118.62
52wk Range92.58 - 126.07
1y Target EstN/A
Market Cap323.19B
P/E Ratio (ttm)22.01
Beta0.70
Volume7,150,518
Avg Vol (3m)6,259,060
Dividend & Yield3.20 (2.73%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C
    Motley Fool4 hours ago

    Hey Gilead, It's Time to Start Looking Over Your Shoulder in Hepatitis C

    This dynamic duo appears to be on track to give Gilead's portfolio of hepatitis C products a run for its money.

  • Reuters4 hours ago

    Morphosys moves closer to getting first antibody drug on market

    German biotech Morphosys moved a step closer to getting its first antibody drug onto the market as its licensee, Johnson & Johnson unit Jenssen, reported positive results from a phase 3 study of psoriasis drug guselkumab. Johnson & Johnson said earlier the experimental biotech drug proved more effective at clearing moderate to severe cases of the skin condition than a placebo or Abbvie's Humira, the world's top-selling prescription medicine. A Morphosys spokesman said on Saturday that guselkumab could now become its first drug to market, depending on whether and when Johnson & Johnson makes an application.

  • Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson
    Motley Fool5 hours ago

    Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson

    Find out which one of these large pharmaceutical companies has more favorable prospects for investors.